BRAF and melanoma: In brain metastases from BRAF V600E melanoma, dabrafenib and vemurafenib, which are BRAF-inhibitors, have been extensively used, with intracranial response rates of 39.2% and 20%, respectively, with dabrafenib having a better brain distribution than vemurafenib [116].